Literature DB >> 34279564

Coffee Consumption and Incident Tachyarrhythmias: Reported Behavior, Mendelian Randomization, and Their Interactions.

Eun-Jeong Kim1, Thomas J Hoffmann2,3, Gregory Nah1, Eric Vittinghoff3, Francesca Delling1, Gregory M Marcus1.   

Abstract

Importance: The notion that caffeine increases the risk of cardiac arrhythmias is common. However, evidence that the consumption of caffeinated products increases the risk of arrhythmias remains poorly substantiated. Objective: To assess the association between consumption of common caffeinated products and the risk of arrhythmias. Design, Setting, and Participants: This prospective cohort study analyzed longitudinal data from the UK Biobank between January 1, 2006, and December 31, 2018. After exclusion criteria were applied, 386 258 individuals were available for analyses. Exposures: Daily coffee intake and genetic polymorphisms that affect caffeine metabolism. Main Outcomes and Measures: Any cardiac arrhythmia, including atrial fibrillation or flutter, supraventricular tachycardia, ventricular tachycardia, premature atrial complexes, and premature ventricular complexes.
Results: A total of 386 258 individuals (mean [SD] age, 56 [8] years; 52.3% female) were assessed. During a mean (SD) follow-up of 4.5 (3.1) years, 16 979 participants developed an incident arrhythmia. After adjustment for demographic characteristics, comorbid conditions, and lifestyle habits, each additional cup of habitual coffee consumed was associated with a 3% lower risk of incident arrhythmia (hazard ratio [HR], 0.97; 95% CI, 0.96-0.98; P < .001). In analyses of each arrhythmia alone, statistically significant associations exhibiting a similar magnitude were observed for atrial fibrillation and/or flutter (HR, 0.97; 95% CI, 0.96-0.98; P < .001) and supraventricular tachycardia (HR, 0.96; 95% CI, 0.94-0.99; P = .002). Two distinct interaction analyses, one using a caffeine metabolism-related polygenic score of 7 genetic polymorphisms and another restricted to CYP1A2 rs762551 alone, did not reveal any evidence of effect modification. A mendelian randomization study that used these same genetic variants revealed no significant association between underlying propensities to differing caffeine metabolism and the risk of incident arrhythmia. Conclusions and Relevance: In this prospective cohort study, greater amounts of habitual coffee consumption were associated with a lower risk of arrhythmia, with no evidence that genetically mediated caffeine metabolism affected that association. Mendelian randomization failed to provide evidence that caffeine consumption was associated with arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34279564      PMCID: PMC8290332          DOI: 10.1001/jamainternmed.2021.3616

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   44.409


  4 in total

1.  Association of Coffee Consumption With Atrial Fibrillation Risk: An Updated Dose-Response Meta-Analysis of Prospective Studies.

Authors:  Yalin Cao; Xiao Liu; Zhengbiao Xue; Kang Yin; Jianyong Ma; Wengen Zhu; Fuwei Liu; Jun Luo; Junyi Sun
Journal:  Front Cardiovasc Med       Date:  2022-07-06

2.  Associations of genetic risk, BMI trajectories, and the risk of non-small cell lung cancer: a population-based cohort study.

Authors:  Dongfang You; Danhua Wang; Yaqian Wu; Xin Chen; Fang Shao; Yongyue Wei; Ruyang Zhang; Theis Lange; Hongxia Ma; Hongyang Xu; Zhibin Hu; David C Christiani; Hongbing Shen; Feng Chen; Yang Zhao
Journal:  BMC Med       Date:  2022-06-06       Impact factor: 11.150

3.  Metabolic Obesity Phenotypes and Risk of Lung Cancer: A Prospective Cohort Study of 450,482 UK Biobank Participants.

Authors:  Fang Shao; Yina Chen; Hongyang Xu; Xin Chen; Jiawei Zhou; Yaqian Wu; Yingdan Tang; Zhongtian Wang; Ruyang Zhang; Theis Lange; Hongxia Ma; Zhibin Hu; Hongbing Shen; David C Christiani; Feng Chen; Yang Zhao; Dongfang You
Journal:  Nutrients       Date:  2022-08-17       Impact factor: 6.706

4.  Economics and outcomes of sotalol in-patient dosing approaches in patients with atrial fibrillation.

Authors:  Daniel L Varela; Tyson S Burnham; Heidi T May; Tami L Bair; Benjamin A Steinberg; Joseph B Muhlestein; Jeffrey L Anderson; Kirk U Knowlton; Thomas Jared Bunch
Journal:  J Cardiovasc Electrophysiol       Date:  2022-01-05       Impact factor: 2.942

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.